↓ Skip to main content

Evolocumab: First Global Approval

Overview of attention for article published in Drugs, September 2015
Altmetric Badge

Mentioned by

1 tweeter


7 Dimensions

Readers on

7 Mendeley
Evolocumab: First Global Approval
Published in
Drugs, September 2015
DOI 10.1007/s40265-015-0460-4
Pubmed ID

Anthony Markham


Evolocumab (Repatha™) is a fully human monoclonal antibody developed by Amgen that has been approved as a treatment for hypercholesterolaemia in the EU, and is awaiting approval in the USA and Japan. It specifically binds proprotein convertase subtilisin/kexin type 9 (PCSK9)-a negative regulator of low-density lipoprotein (LDL)-receptors-thereby improving the ability of the liver to bind LDL-cholesterol (LDL-C), leading to reduced LDL-C blood levels. The drug reduces LDL-C levels in patients with hypercholesterolaemia when used as monotherapy or in conjunction with a statin. This article summarizes the milestones in the development of evolocumab leading to this approval for the treatment of adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia as an adjunct to diet with or without a statin and/or other lipid lowering therapies, and in adults and adolescents aged ≥12 years with homozygous familial hypercholesterolaemia in combination with other lipid lowering therapies.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 7 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Netherlands 1 14%
New Zealand 1 14%
Unknown 5 71%

Demographic breakdown

Readers by professional status Count As %
Researcher 6 86%
Student > Postgraduate 5 71%
Student > Ph. D. Student 5 71%
Student > Bachelor 3 43%
Other 3 43%
Other 8 114%
Readers by discipline Count As %
Medicine and Dentistry 12 171%
Agricultural and Biological Sciences 5 71%
Unspecified 5 71%
Pharmacology, Toxicology and Pharmaceutical Science 3 43%
Biochemistry, Genetics and Molecular Biology 2 29%
Other 3 43%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 04 September 2015.
All research outputs
of 6,251,511 outputs
Outputs from Drugs
of 1,171 outputs
Outputs of similar age
of 194,433 outputs
Outputs of similar age from Drugs
of 34 outputs
Altmetric has tracked 6,251,511 research outputs across all sources so far. This one is in the 14th percentile – i.e., 14% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,171 research outputs from this source. They receive a mean Attention Score of 3.4. This one is in the 7th percentile – i.e., 7% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 194,433 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 19th percentile – i.e., 19% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 34 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.